Publications - Mother to Child Transmission of HIV
-
Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
Citation: Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Sarah Bradford, Tsungai Chipato, Tichaona Vhembo, Lynda Stranix-Chibanda, Deo Wabwire, Gaerolwe Masheto, Patrick Jean-Philippe, Timothy R Sterling, Adriana Weinberg, Amita Gupta, for the IMPAACT P1078 TB APPRISE Study Team, Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics, Clinical Infectious Diseases, 2025;, ciaf198, https://doi.org/10.1093/cid/ciaf198
Published: 05/14/2025
-
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial
Citation: Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner A, Costello D, Kulkarni V, Shayo A, Kabugho E, Jean-Phillippe P, Chakhtoura N, Sterling TR, Theron G, Weinberg A; IMPAACT P1078 TB APPRISE Study Team. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023 Aug 24:S2352-4642(23)00174-8. doi: 10.1016/S2352-4642(23)00174-8. Epub ahead of print. PMID: 37634517.
Published: 09/08/2023
-
Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women
Citation: Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women. Clin Infect Dis. 2020 Nov 4:ciaa1674. doi: 10.1093/cid/ciaa1674. Epub ahead of print. PMID: 33146706.
Published: 11/04/2020
-
TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence
Citation: Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence. J Int AIDS Soc. 2020 Mar;23(3):e25481. doi: 10.1002/jia2.25481. PMID: 32202066.
Published: 03/23/2020
-
Isoniazid preventive therapy in HIV-infected pregnant and postpartum women
Citation: Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.
Published: 10/03/2019
-
Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons
Citation: Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med. 2019 Aug 15;16(8): e1002882. https://doi.org/10.1371/journal.pmed.1002882. PMID: 31415563 PMCID: PMC6695091.
Published: 08/15/2019
-
Risk factors for adverse birth outcomes in the PROMISE 1077BF/1077FF Trial
Citation: Sebikari D, Farhad M, Fenton T, Owor M, Stringer JSA, Qin M, Chakhtoura N, Chi BH, Saidi F, Nevrekar N, Violari A, Chipato T, McIntyre JA, Moodley D, Taha TE, Theron G, Fowler MG. Risk factors for adverse birth outcomes in the PROMISE 1077BF/1077FF Trial. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):521-532. doi: 10.1097/QAI.0000000000002072. PMID: 31295174; PubMed PMCID: PMC6702964.
Published: 08/15/2019
-
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial
Citation: Hoffman RM, Angelidou KN, Brummel SS, Saidi F, Violari A, Dula D, Mave V, Fairlie L, Theron G, Kamateeka M, Chipato T, Chi BH, Stranix-Chibanda L, Nematadzira T, Moodley D, Bhattacharya D, Gupta A, Coletti A, McIntyre JA, Klingman KL, Chakhtoura N, Shapiro DE, Fowler MG, Currier JS for the IMPAACT PROMISE 1077BF/FF team. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clin Trials. 2018 Dec;19(6):209-224. doi: 10.1080/15284336.2018.1537327.
Published: 12/15/2018
-
Prevention of HIV-1 transmission through breastfeeding:efficacy of safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE)
Citation: Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Ganashanmugam D, Chakhtoura N, McCarthy K, ,Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE, PROMISE Study Team. Prevention of HIV-1 transmission through breastfeeding: efficacy of safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. J Acquir Immune Defic Syndr 2018 Apr 1:77(4):383-392. doi: 10.1097/QAI.0000000000001612. PMID: 29239901, PMCID: PMC5825265.
Published: 04/01/2018
-
Maternal syphilis: an independent risk factor for mother to infant human immunodeficiency virus transmission
Citation: Kinikar A, Gupte N, Bhat J, Bharadwaj R, Kulkarni V, Bhosale R, McIntire KN, Mave V, Suryavanshi N, Patil S, Bollinger R, Gupta A. Maternal syphilis: an independent risk factor for mother to infant human immunodeficiency virus transmission. Sex Transm Dis. 2017 Jun;44(6):371-375. doi: 10.1097/OLQ.0000000000000622. PMID: 28499289 PMCID: PMC5434955
Published: 06/15/2017
-
Benefits and risks of antiretroviral therapy for perinatal HIV prevention
Citation: Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM; IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737. PMID: 27806243; PMCID: PMC5214343
Published: 11/03/2016
-
Cost effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India
Citation: Kapoor S, Gupta A, Shah M. Cost effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis. 2016 Jan;20(1):85-92. doi: 10.5588/ijtld.15.0391. PMID: 26688533. PMCID: PMC4992362.
Published: 01/15/2016
-
Vitamin D deficiency and risk of postpartum tuberculosis among HIV-infected breastfeeding mothers in breastfeeding mothers in India
Citation: Mave V, Chandanwale A, Bhosale R, Shere D, Gupte N, Suryavanshi N, Kulkarni V, Kagal A, Bharadwaj R, Joshi S, Bollinger R, Gupta A. Vitamin D deficiency and risk of postpartum tuberculosis among HIV-infected breastfeeding mothers in breastfeeding mothers in India. Int J Tuberc Lung Dis. 2015 Mar;19(3):302-4. doi: 10.5588/ijtld.14.0658. PMID: 25686138.
Published: 03/11/2015
-
Blood stream infections
Citation: Bharadwaj R, Bal A, Kapila K, Mave V, Gupta A. Blood stream infections. Biomed Res Int. 2014;2014:515273. doi: 10.1155/2014/515273. Epub 2014 Jul 1. PMID: 25093174. PMCID: PMC4100346.
Published: 03/11/2015
-
Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs
Citation: Gupta A, Mathad JS, Yang WT, Singh HK, Gupte N, Mave V, Bharadwaj R, Zaman K,Roy E, Bollinger RC, Bhosale R, Steinhoff MC. Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs. Vaccine. 2014 Mar 14;32(13):1466-72. doi: 10.1016/j.vaccine.2014.01.033. Epub 2014 Jan 30. PMID: 24486350. PMCID: PMC3975143.
Published: 03/11/2015
-
Vitamin D deficiency is common among HIV-infected breastfeeding mothers in Pune, India, but is not associated with mother-to-child HIV transmission
Citation: Mave V, Shere D, Gupte N, Suryavanshi N, Kulkarni V, Patil S, Khandekar M, Kinikar A, Bharadwaj R, Bhosale R, Sambarey P, Chandanwale A, Bollinger R, Gupta A; SWEN India and Byramjee-Jeejeebhoy Medical College Clinical Trials Unit Study Team. Vitamin D deficiency is common among HIV-infected breastfeeding mothers in Pune, India, but is not associated with mother-to-child HIV transmission. HIV Clin Trials. 2012 Sep-Oct;13(5):278-83. doi: 10.1310/hct1305-278. PMID: 23134628.
Published: 03/11/2015
-
Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count
Citation: Omer SB, Six Week Extended Dose Nevirapine (SWEN) Study Team. Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS. 2011 Mar 27;25(6):767-76. doi: 10.1097/QAD.0b013e328344c12a. PMID: 21330912.
Published: 03/11/2015
-
Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus
Citation: Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, Joshi S, Khandekar M, Karmarkar A, Kulkarni V, Sastry J, Mave V, Suryavanshi N, Thakar M, Kulkarni S, Tripathy S, Sambarey P, Patil S, Paranjape R, Bollinger RC, Jamkar A; Six Week Extended-Dose Nevirapine (SWEN) India Study Team. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011 Feb 1;203(3):358-63. doi: 10.1093/infdis/jiq064. PMID: 21208928. PMCID: PMC3071111.
Published: 03/11/2015
-
Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study
Citation: Yeganeh N, Watts HD, Camarca M, Soares G, Joao E, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata M, Ceriotto M, Machado DM, Grinzstejn B, Veloso VG, Morgado MG, Bryson Y, Mofenson LM, Nielsen-Saines K; NICHD HPTN 040P1043 Study Team. Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study. Pediatr Infect Dis J. 2015 Mar;34(3):e52-7. doi: 10.1097/INF.0000000000000578. Erratum in: Pediatr Infect Dis J. 2015 Sep;34(9):1038. PMID: 25742089; PMCID: PMC4352722
Published: 03/01/2015
-
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A
Citation: Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538. PMID: 25232777; PMCID: PMC4355059
Published: 02/01/2015
-
Growth patterns in the first year of life differ in infants born to perinatally vs. HIV-infected women
Citation: Jao J, Agwu A, Mhango G, Kim A, Park K, Posada R, Abrams EJ, Hutton N, Sperling RS. Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women. AIDS. 2015 Jan 2;29(1):111-6. doi: 10.1097/QAD.0000000000000501. PMID: 25562495; PMCID: PMC4326225
Published: 01/02/2015
-
Challenges to disclosure of HIV status to perinatally infected children: a study of caregiver perspectives in Pune, India
Citation: Suryavanshi N, Raval G, Kanade S, Nimkar S, Nadgiri V, Sahu P, Kadam D, Khadse S, Mave V, Gupte N, Gupta A. Challenges to disclosure of HIV status to perinatally infected children: a study of caregiver perspe study of caregiver perspectives in Pune, India. Journal of Pediatric Infectious Diseases, 9(2), 71-84. DOI: 10.3233/JPI-140418.
Published: 09/15/2014
-
Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV
Citation: Mave V, Suryavanshi N, Kulkarni V, Balasubramanian U, Jadhav A, Bhattacharya D, Patil S, Khandekar M, Paranjape R, Tripathy S, Kinikar A, Bharadwaj R, Bhosale RA, Sambarey P, Jamkar A, Sastry J, Bollinger RC, Gupta A for the SWEN India Study team. Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV. HIV Med. 2014 Jul;15(6):347-54. doi: 10.1111/hiv.12120. Epub 2014 Jan 14. PMID: 24422893. PMCID: PMC4055515.
Published: 07/15/2014
-
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years
Citation: Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21. PMID: 24145879; PMCID: PMC3890333
Published: 02/01/2014
-
High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)
Citation: Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham CK, Spector SA, Nachman S, Siberry GK, Handelsman E, Flynn PM; IMPAACT P1088 study team. High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Hum Vaccin Immunother. 2013 May;9(5):957-68. doi: 10.4161/hv.23774. Epub 2013 Jan 31. PMID: 23370281; PMCID: PMC3899162
Published: 05/01/2013
-
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants
Citation: Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, Thakar M, Bharadwaj R, Kagal A, Bhore AV, Patil S, Kulkarni V, Venkataramani V, Balasubramanian U, Suryavanshi N, Ziemniak C, Gupte N, Bollinger R, Persaud D. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One. 2009;4(1):e4096. doi: 10.1371/journal.pone.0004096. PMID: 19119321. PMCID: PMC2606064.
Published: 04/15/2009
-
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding transmission in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials
Citation: Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S, Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008 Jul 26;372(9635):300-13. doi: 10.1016/S0140-6736(08)61114-9. PMID: 18657709.
Published: 07/11/2008